Pharmaceuticals
PreCheck Program Expands Manufacturing
The PreCheck program was launched to boost domestic pharmaceutical manufacturing in the US. It focuses on increasing production capacity and supply chain resilience. Regulatory developments also include blood-based tests for Alzheimer's detection.
Lawsuits claim Tylenol use in pregnancy causes autism
AI에 의해 보고됨
More than 100 lawsuits have been filed against acetaminophen manufacturers, including Johnson & Johnson, alleging that the drug's use during pregnancy increases the risk of autism and ADHD in children. These legal actions stem from scientific studies showing associations between prenatal exposure and neurodevelopmental disorders. The cases highlight growing concerns over the safety of a widely used pain reliever.
Pfizer stock rises after aligning with Trump on drug pricing
AI에 의해 보고됨
Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.
FDA Approves Injectable Form of Merck's Keytruda
The U.S. Food and Drug Administration has granted approval for an injectable version of Merck's blockbuster cancer drug Keytruda, marking a significant advancement in treatment options for patients with certain types of cancer. This subcutaneous formulation promises greater convenience over the traditional intravenous method, potentially improving patient adherence and reducing healthcare burdens. The decision, announced on September 19, 2025, underscores ongoing innovations in oncology amid rising demands for more accessible therapies.
Drug combo cuts prostate cancer death risk by over 40 percent
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.